Medical-device makers drew a lot of attention on Friday after shares of both Angiotech Pharmaceuticals ( ANPI) and Boston Scientific ( BSX) were halted, pending news.

With neither company trading and the news still unreleased, rumors drove shares of Boston Scientific's rivals higher, specifically other stent manufacturers.

Early in the session, Reuters reported that Brigham & Women's Hospital in Massachusetts had pulled Boston Scientific's Taxus stent from its shelves after the company recalled 200 of the devices at the beginning of the month.

Boston Scientific, which releases earnings this coming Monday, said it will issue a press release later Friday, but in the meantime, speculation was running high that trouble is brewing for Taxus.

Bad news on Taxus would be a big blow for Boston Scientific. Taxus was just approved four months ago and had already begun eating into sales of Johnson & Johnson's ( JNJ) Cypher stent, winning 70% market share as of the second quarter.

As a result of the recent speculation, shares of Johnson & Johnson rose $1.70, or 3.1%, to $57.05, while shares of Guidant ( GDT), which is also working on a stent, were up $1.75, or 3.3%, to $55. Medtronic ( MDT), whose Endeavor stent is already on sale in Europe, rose 68 cents, or 1.4%, to $50.24.